托莫西汀在注意力缺陷多动障碍患儿中的精准药学研究：CYP2D6基因检测和治疗药物监测

约3%的孕妇患有慢性肾脏病（chronic kidney disease，CKD）。该文复习了关于CKD母亲（包括透析和肾移植患者）的新生儿结局的文献。文献显示：妊娠合并CKD会增加新生儿发生早产、低出生体重及小于胎龄儿的风险，但不增加发生先天结构畸形的风险；从远期结局来看，对子代体格发育、免疫功能无显著影响；子代的神经发育结局与早产、低出生体重相关，与宫内药物暴露无关。仍需更进一步的研究及随访以探讨CKD母亲的新生儿结局。

A precision medication study of atomoxetine in children with attention deficit hyperactivity disorder: CYP2D6 genetic testing and therapeutic drug monitoring

About 3% of pregnant women suffer from chronic kidney disease (CKD). This article reviews the literature on the outcomes of neonates born to mothers with CKD (including those undergoing dialysis and kidney transplantation), and the results show that CKD during pregnancy may increase the risk of preterm birth, low birth weight, and small for gestational age infant, but it does not increase the risk of congenital anomalies. As for long-term outcomes, CKD during pregnancy has no significant impact on offspring's physical development and immune function. Neurodevelopmental outcome of offspring is associated with preterm birth and low birth weight, rather than intrauterine drug exposure. However, further research and follow-up are needed to investigate the outcome of neonates born to mothers with CKD.